Update  ||| S:0 E:7 ||| NNP
on  ||| S:7 E:10 ||| IN
laboratory  ||| S:10 E:21 ||| NN
tests  ||| S:21 E:27 ||| NNS
for  ||| S:27 E:31 ||| IN
the  ||| S:31 E:35 ||| DT
diagnosis  ||| S:35 E:45 ||| NN
and  ||| S:45 E:49 ||| CC
differentiation  ||| S:49 E:65 ||| NN
of  ||| S:65 E:68 ||| IN
hereditary  ||| S:68 E:79 ||| JJ
angioedema  ||| S:79 E:90 ||| NN
and  ||| S:90 E:94 ||| CC
acquired  ||| S:94 E:103 ||| VBD
angioedema  ||| S:103 E:114 ||| VBN
The  ||| S:114 E:118 ||| DT
importance  ||| S:118 E:129 ||| NN
of  ||| S:129 E:132 ||| IN
laboratory  ||| S:132 E:143 ||| NN
testing  ||| S:143 E:151 ||| NN
in  ||| S:151 E:154 ||| IN
the  ||| S:154 E:158 ||| DT
diagnosis  ||| S:158 E:168 ||| NN
of  ||| S:168 E:171 ||| IN
hereditary  ||| S:171 E:182 ||| JJ
angioedema  ||| S:182 E:193 ||| NNS
( ||| S:193 E:194 ||| -LRB-
HAE ||| S:194 E:197 ||| NNP
)  ||| S:197 E:199 ||| -RRB-
has  ||| S:199 E:203 ||| VBZ
increased  ||| S:203 E:213 ||| VBN
with  ||| S:213 E:218 ||| IN
the  ||| S:218 E:222 ||| DT
advent  ||| S:222 E:229 ||| NN
of  ||| S:229 E:232 ||| IN
new  ||| S:232 E:236 ||| JJ
treatment  ||| S:236 E:246 ||| NN
options  ||| S:246 E:254 ||| NNS
in  ||| S:254 E:257 ||| IN
recent  ||| S:257 E:264 ||| JJ
years ||| S:264 E:269 ||| NNS
.  ||| S:269 E:271 ||| .
It  ||| S:271 E:274 ||| PRP
has  ||| S:274 E:278 ||| VBZ
been  ||| S:278 E:283 ||| VBN
50  ||| S:283 E:286 ||| CD
years  ||| S:286 E:292 ||| NNS
since  ||| S:292 E:298 ||| IN
HAE  ||| S:298 E:302 ||| NNP
was  ||| S:302 E:306 ||| VBD
linked  ||| S:306 E:313 ||| VBN
to  ||| S:313 E:316 ||| TO
a  ||| S:316 E:318 ||| DT
decrease  ||| S:318 E:327 ||| NN
of  ||| S:327 E:330 ||| IN
C1INH  ||| S:330 E:336 ||| NNP
( ||| S:336 E:337 ||| -LRB-
the  ||| S:337 E:341 ||| DT
inhibitor  ||| S:341 E:351 ||| NN
of  ||| S:351 E:354 ||| IN
complement  ||| S:354 E:365 ||| JJ
enzyme ||| S:365 E:371 ||| NN
,  ||| S:371 E:373 ||| ,
C1  ||| S:373 E:376 ||| CD
esterase ||| S:376 E:384 ||| CD
) ||| S:384 E:385 ||| -RRB-
,  ||| S:385 E:387 ||| ,
a  ||| S:387 E:389 ||| DT
link  ||| S:389 E:394 ||| NN
that  ||| S:394 E:399 ||| WDT
provided  ||| S:399 E:408 ||| VBD
for  ||| S:408 E:412 ||| IN
the  ||| S:412 E:416 ||| DT
first  ||| S:416 E:422 ||| JJ
laboratory  ||| S:422 E:433 ||| NN
test  ||| S:433 E:438 ||| NN
available  ||| S:438 E:448 ||| JJ
for  ||| S:448 E:452 ||| IN
this  ||| S:452 E:457 ||| DT
disorder ||| S:457 E:465 ||| NN
.  ||| S:465 E:467 ||| .
HAE  ||| S:467 E:471 ||| NNP
is  ||| S:471 E:474 ||| VBZ
subdivided  ||| S:474 E:485 ||| VBN
into  ||| S:485 E:490 ||| IN
types  ||| S:490 E:496 ||| NNS
that  ||| S:496 E:501 ||| WDT
can  ||| S:501 E:505 ||| MD
be  ||| S:505 E:508 ||| VB
differentiated  ||| S:508 E:523 ||| VBN
only  ||| S:523 E:528 ||| RB
by  ||| S:528 E:531 ||| IN
laboratory  ||| S:531 E:542 ||| NN
testing ||| S:542 E:549 ||| NN
.  ||| S:549 E:551 ||| .
The  ||| S:551 E:555 ||| DT
Type  ||| S:555 E:560 ||| NNP
I  ||| S:560 E:562 ||| NNP
form  ||| S:562 E:567 ||| NN
is  ||| S:567 E:570 ||| VBZ
characterized  ||| S:570 E:584 ||| VBN
by  ||| S:584 E:587 ||| IN
low  ||| S:587 E:591 ||| JJ
levels  ||| S:591 E:598 ||| NNS
and  ||| S:598 E:602 ||| CC
function  ||| S:602 E:611 ||| NN
of  ||| S:611 E:614 ||| IN
C1INH  ||| S:614 E:620 ||| CD
in  ||| S:620 E:623 ||| IN
the  ||| S:623 E:627 ||| DT
circulation ||| S:627 E:638 ||| NN
.  ||| S:638 E:640 ||| .
The  ||| S:640 E:644 ||| DT
Type  ||| S:644 E:649 ||| NNP
II  ||| S:649 E:652 ||| NNP
form  ||| S:652 E:657 ||| NN
is  ||| S:657 E:660 ||| VBZ
characterized  ||| S:660 E:674 ||| VBN
by  ||| S:674 E:677 ||| IN
normal  ||| S:677 E:684 ||| JJ
levels  ||| S:684 E:691 ||| NNS
of  ||| S:691 E:694 ||| IN
C1INH ||| S:694 E:699 ||| NNP
,  ||| S:699 E:701 ||| ,
but  ||| S:701 E:705 ||| CC
low  ||| S:705 E:709 ||| JJ
function ||| S:709 E:717 ||| NN
.  ||| S:717 E:719 ||| .
Sample  ||| S:719 E:726 ||| NN
collection  ||| S:726 E:737 ||| NN
and  ||| S:737 E:741 ||| CC
handling  ||| S:741 E:750 ||| NN
is  ||| S:750 E:753 ||| VBZ
critical  ||| S:753 E:762 ||| JJ
for  ||| S:762 E:766 ||| IN
the  ||| S:766 E:770 ||| DT
functional  ||| S:770 E:781 ||| JJ
assays ||| S:781 E:787 ||| NN
.  ||| S:787 E:789 ||| .
The  ||| S:789 E:793 ||| DT
serum  ||| S:793 E:799 ||| JJ
samples  ||| S:799 E:807 ||| NNS
for  ||| S:807 E:811 ||| IN
the  ||| S:811 E:815 ||| DT
functional  ||| S:815 E:826 ||| JJ
analysis  ||| S:826 E:835 ||| NN
must  ||| S:835 E:840 ||| MD
be  ||| S:840 E:843 ||| VB
collected ||| S:843 E:852 ||| VBN
,  ||| S:852 E:854 ||| ,
separated ||| S:854 E:863 ||| NN
,  ||| S:863 E:865 ||| ,
and  ||| S:865 E:869 ||| CC
frozen  ||| S:869 E:876 ||| VBN
at  ||| S:876 E:879 ||| IN
less  ||| S:879 E:884 ||| JJR
than  ||| S:884 E:889 ||| IN
-60Â°C  ||| S:889 E:895 ||| CD
within  ||| S:895 E:902 ||| IN
2  ||| S:902 E:904 ||| CD
hours  ||| S:904 E:910 ||| NNS
of  ||| S:910 E:913 ||| IN
the  ||| S:913 E:917 ||| DT
blood  ||| S:917 E:923 ||| NN
draw ||| S:923 E:927 ||| NN
.  ||| S:927 E:929 ||| .
Additionally  ||| S:929 E:942 ||| RB
some  ||| S:942 E:947 ||| DT
suspected  ||| S:947 E:957 ||| JJ
Type  ||| S:957 E:962 ||| NNP
II  ||| S:962 E:965 ||| NNP
patients  ||| S:965 E:974 ||| NNS
may  ||| S:974 E:978 ||| MD
benefit  ||| S:978 E:986 ||| VB
from  ||| S:986 E:991 ||| IN
looking  ||| S:991 E:999 ||| VBG
closely  ||| S:999 E:1007 ||| RB
at  ||| S:1007 E:1010 ||| IN
what  ||| S:1010 E:1015 ||| WP
method  ||| S:1015 E:1022 ||| NN
is  ||| S:1022 E:1025 ||| VBZ
used  ||| S:1025 E:1030 ||| VBN
for  ||| S:1030 E:1034 ||| IN
the  ||| S:1034 E:1038 ||| DT
functional  ||| S:1038 E:1049 ||| JJ
testing ||| S:1049 E:1056 ||| NN
.  ||| S:1056 E:1058 ||| .
The  ||| S:1058 E:1062 ||| DT
acquired  ||| S:1062 E:1071 ||| JJ
forms  ||| S:1071 E:1077 ||| NNS
of  ||| S:1077 E:1080 ||| IN
angioedema  ||| S:1080 E:1091 ||| NNS
( ||| S:1091 E:1092 ||| -LRB-
AAE ||| S:1092 E:1095 ||| NNP
)  ||| S:1095 E:1097 ||| -RRB-
can  ||| S:1097 E:1101 ||| MD
benefit  ||| S:1101 E:1109 ||| VB
from  ||| S:1109 E:1114 ||| IN
the  ||| S:1114 E:1118 ||| DT
same  ||| S:1118 E:1123 ||| JJ
clinical  ||| S:1123 E:1132 ||| JJ
testing ||| S:1132 E:1139 ||| NN
,  ||| S:1139 E:1141 ||| ,
because  ||| S:1141 E:1149 ||| IN
most  ||| S:1149 E:1154 ||| JJS
are  ||| S:1154 E:1158 ||| VBP
ultimately  ||| S:1158 E:1169 ||| RB
due  ||| S:1169 E:1173 ||| JJ
to  ||| S:1173 E:1176 ||| TO
decreased  ||| S:1176 E:1186 ||| CD
C1INH ||| S:1186 E:1191 ||| CD
.  ||| S:1191 E:1193 ||| .
Measurement  ||| S:1193 E:1205 ||| NN
of  ||| S:1205 E:1208 ||| IN
C1q  ||| S:1208 E:1212 ||| CD
levels  ||| S:1212 E:1219 ||| NNS
and  ||| S:1219 E:1223 ||| CC
testing  ||| S:1223 E:1231 ||| NN
for  ||| S:1231 E:1235 ||| IN
anti-C1INH  ||| S:1235 E:1246 ||| CD
autoantibodies  ||| S:1246 E:1261 ||| NNS
can  ||| S:1261 E:1265 ||| MD
help  ||| S:1265 E:1270 ||| VB
differentiate  ||| S:1270 E:1284 ||| JJ
AAE  ||| S:1284 E:1288 ||| NN
from  ||| S:1288 E:1293 ||| IN
HAE ||| S:1293 E:1296 ||| NNP
.  ||| S:1296 E:1298 ||| .
Diagnostic  ||| S:1298 E:1309 ||| JJ
testing  ||| S:1309 E:1317 ||| NN
for  ||| S:1317 E:1321 ||| IN
the  ||| S:1321 E:1325 ||| DT
third  ||| S:1325 E:1331 ||| JJ
hereditary  ||| S:1331 E:1342 ||| JJ
form ||| S:1342 E:1346 ||| NN
,  ||| S:1346 E:1348 ||| ,
alternately  ||| S:1348 E:1360 ||| VBD
called  ||| S:1360 E:1367 ||| VBN
estrogen-dependent  ||| S:1367 E:1386 ||| JJ
HAE ||| S:1386 E:1389 ||| NNP
,  ||| S:1389 E:1391 ||| ,
HAE  ||| S:1391 E:1395 ||| NNP
with  ||| S:1395 E:1400 ||| IN
Normal  ||| S:1400 E:1407 ||| NNP
C1INH  ||| S:1407 E:1413 ||| NNP
or  ||| S:1413 E:1416 ||| CC
HAE  ||| S:1416 E:1420 ||| NNP
Type  ||| S:1420 E:1425 ||| NNP
III ||| S:1425 E:1428 ||| NNP
,  ||| S:1428 E:1430 ||| ,
still  ||| S:1430 E:1436 ||| RB
presents  ||| S:1436 E:1445 ||| JJ
challenges ||| S:1445 E:1455 ||| NNS
,  ||| S:1455 E:1457 ||| ,
and  ||| S:1457 E:1461 ||| CC
definitive  ||| S:1461 E:1472 ||| JJ
testing  ||| S:1472 E:1480 ||| NN
may  ||| S:1480 E:1484 ||| MD
have  ||| S:1484 E:1489 ||| VB
to  ||| S:1489 E:1492 ||| TO
wait  ||| S:1492 E:1497 ||| VB
until  ||| S:1497 E:1503 ||| IN
there  ||| S:1503 E:1509 ||| EX
is  ||| S:1509 E:1512 ||| VBZ
a  ||| S:1512 E:1514 ||| DT
more  ||| S:1514 E:1519 ||| RBR
complete  ||| S:1519 E:1528 ||| JJ
understanding  ||| S:1528 E:1542 ||| NN
of  ||| S:1542 E:1545 ||| IN
this  ||| S:1545 E:1550 ||| DT
mixed  ||| S:1550 E:1556 ||| JJ
group  ||| S:1556 E:1562 ||| NN
of  ||| S:1562 E:1565 ||| IN
patients ||| S:1565 E:1573 ||| NNS
.  ||| S:1573 E:1575 ||| .
The  ||| S:1575 E:1579 ||| DT
next  ||| S:1579 E:1584 ||| JJ
steps  ||| S:1584 E:1590 ||| NNS
will  ||| S:1590 E:1595 ||| MD
include  ||| S:1595 E:1603 ||| VB
genetic  ||| S:1603 E:1611 ||| JJ
analysis  ||| S:1611 E:1620 ||| NN
of  ||| S:1620 E:1623 ||| IN
C1INH  ||| S:1623 E:1629 ||| NNP
and  ||| S:1629 E:1633 ||| CC
other  ||| S:1633 E:1639 ||| JJ
proteins  ||| S:1639 E:1648 ||| NNS
involved  ||| S:1648 E:1657 ||| VBN
in  ||| S:1657 E:1660 ||| IN
HAE ||| S:1660 E:1663 ||| NNP
.  ||| S:1663 E:1665 ||| .
